KELLY HOOVER: Open Payments
NPI 1366809923 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,486 in 197 payments from 16 companies in 2025. Trend: 2023 $2,712 · 2024 $3,001 · 2025 $3,486
Food & beverage: $3,375Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 34 | $642 |
| Vanda Pharmaceuticals Inc. | 22 | $404 |
| Alkermes, Inc. | 24 | $386 |
| Teva Pharmaceuticals USA, Inc. | 17 | $356 |
| E.R. Squibb & Sons, L.L.C. | 16 | $340 |
| ABBVIE INC. | 22 | $316 |
| Otsuka America Pharmaceutical, Inc. | 19 | $268 |
| Janssen Pharmaceuticals, Inc | 9 | $174 |
| Lundbeck LLC | 13 | $172 |
| Supernus Pharmaceuticals, Inc. | 6 | $141 |
Products named: CAPLYTA, ARISTADA, COBENFY, VRAYLAR, REXULTI, HETLIOZ, FANAPT, Qelbree.
Industry payments across NE — which companies pay providers there.
